Home Featured

Featured

Random

BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets

Prophecy, Psychedelics, and Power in Dune

Free Webinar – NueLife: Empowering Patients with At-Home Ketamine Therapy

PT371 – The Trickster Archetype and the Need for Comic Relief

When it Comes to Psychedelic Access, It’s the Messenger, Not the...

Dr Jason Konner – Psychedelic Oncology and the Future of Cancer...

MINDCURE Launches “Desire Project” To Treat Female Hypoactive Sexual Desire Disorder...

Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1...

Filament Cultivates 20th Psychedelic Mushroom Variety and Provides Propagation Update

Cybin Announces Senior Management Changes to Lead Buildout of Development and...

Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression...

COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial...

Horizons ETFs Announces Methodology Update for the North American Psychedelics Index

PT352 – Alex Enchin & Ian-Michael Hébert, MA – HOLOS: Returning...

12 3...312 Page 1 of 312

EDITOR PICKS

Film Club: Music for Mushrooms

Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on...

Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research,...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.